Trishula Therapeutics

Trishula Therapeutics is a privately held, clinical-stage immuno-oncology company developing cancer immunotherapies that target immune-evasion mechanisms in the tumor microenvironment. Its lead candidate, TTX-030, is a first-in-class monoclonal antibody that inhibits CD39, an enzyme in the adenosine pathway that tumors exploit to suppress anti-tumor immunity; TTX-030 has advanced into Phase 2 clinical trials, including studies in metastatic pancreatic cancer. The company was surfaced through the API Evangelist network as a portfolio company of Canaan Partners. It is a therapeutics company with a corporate web presence and no public API, developer, or software product surface.

Trishula Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immuno-Oncology, Pharmaceuticals, and Cancer.

Trishula Therapeutics’ developer surface includes engineering blog and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
3.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyImmuno-OncologyPharmaceuticalsCancerTherapeuticsClinical StageImmunotherapy

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.8/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/trishula-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Trishula Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 4

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: trishula-therapeutics
name: Trishula Therapeutics
description: Trishula Therapeutics is a privately held, clinical-stage immuno-oncology company developing cancer immunotherapies
  that target immune-evasion mechanisms in the tumor microenvironment. Its lead candidate, TTX-030, is a first-in-class monoclonal
  antibody that inhibits CD39, an enzyme in the adenosine pathway that tumors exploit to suppress anti-tumor immunity; TTX-030
  has advanced into Phase 2 clinical trials, including studies in metastatic pancreatic cancer. The company was surfaced through
  the API Evangelist network as a portfolio company of Canaan Partners. It is a therapeutics company with a corporate web
  presence and no public API, developer, or software product surface.
url: https://raw.githubusercontent.com/api-evangelist/trishula-therapeutics/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.trishulatx.com/themes/default/images/logo.svg
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
- Clinical Stage
- Immunotherapy
apis: []
common:
- type: DomainSecurity
  url: security/trishula-therapeutics-domain-security.yml
- type: Website
  url: https://www.trishulatx.com
- type: About
  url: https://www.trishulatx.com/about/
- type: Blog
  name: News
  url: https://www.trishulatx.com/news/
- type: LinkedIn
  url: https://www.linkedin.com/company/trishulatx/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1